Key facts
- Notable investors include Christian Nielsen's Fund, Innovationsfonden.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Tissue-Link
- ·The full record, as it builds
Funding rounds
No funding rounds for Tissue-Link are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tissue-Link
Developer of innovative hemostatic medical devices designed to manage severe bleeding. The company specializes in developing advanced products like their tissue-based technology that rapidly initiates clot formation by activating the body's natural coagulation process, providing doctors with effective products that significantly reduce bleeding and improve patient outcomes in emergency and surgical settings.
- Sector
- Healthcare
- HQ
- København N, Denmark
- Founded
- 2019
- Employees
- 1
- Website
- tissue-link.com/
- Ownership
- Privately Held (backing)
Tissue-Link doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tissue-Link shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tissue-Link in its N-PORT filings yet. We sweep new filings monthly.